Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

Condition:   Neoplasms Interventions:   Drug: Nilotinib;   Drug: Paclitaxel Sponsor:   National Cancer Institute (NCI) Not yet recruiting

Source: ClinicalTrials.gov - June 29, 2020 Category: Research Source Type: clinical trials